112 related articles for article (PubMed ID: 7475964)
1. Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding.
Zernig G; Issaevitch T; Broadbear JH; Burke TF; Lewis JW; Brine GA; Woods JH
Life Sci; 1995; 57(23):2113-25. PubMed ID: 7475964
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
3. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
4. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
Paronis CA; Woods JH
Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
[TBL] [Abstract][Full Text] [Related]
5. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
6. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
7. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
Chan KW; Duttory A; Yoburn BC
Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
[TBL] [Abstract][Full Text] [Related]
8. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
9. Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon.
Zernig G; Saria A; Krassnig R; Schmidhammer H
Life Sci; 2000 Mar; 66(19):1871-7. PubMed ID: 10809184
[TBL] [Abstract][Full Text] [Related]
10. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
11. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
[TBL] [Abstract][Full Text] [Related]
12. Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception.
Zernig G; Lewis JW; Woods JH
Psychopharmacology (Berl); 1997 Feb; 129(3):233-42. PubMed ID: 9084061
[TBL] [Abstract][Full Text] [Related]
13. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
Walker EA; Young AM
J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
[TBL] [Abstract][Full Text] [Related]
14. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats.
Walker EA; Young AM
Psychopharmacology (Berl); 2001 Mar; 154(2):131-42. PubMed ID: 11314675
[TBL] [Abstract][Full Text] [Related]
15. Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys.
Butelman ER; Negus SS; Lewis JW; Woods JH
Psychopharmacology (Berl); 1996 Feb; 123(4):320-4. PubMed ID: 8867870
[TBL] [Abstract][Full Text] [Related]
16. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
17. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
18. In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay.
Walker EA; Zernig G; Young AM
Psychopharmacology (Berl); 1998 Mar; 136(1):15-23. PubMed ID: 9537678
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
Peckham EM; Barkley LM; Divin MF; Cicero TJ; Traynor JR
Brain Res; 2005 Oct; 1058(1-2):137-47. PubMed ID: 16139823
[TBL] [Abstract][Full Text] [Related]
20. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
